VPC
DYN icon

Vestal Point Capital’s Dyne Therapeutics DYN Stock Holding History

Vestal Point Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75M Sell
3,375,000
-625,000
-16% -$11.6M 1.75% 20
2026
Q1 		$72.5M Buy
4,000,000
+3,880,000
+3,233% +$66.9M 2.03% 14
2025
Q4 		$2.35M Sell
120,000
-2,655,000
-96% -$50.3M 0.08% 69
2025
Q3 		$35.1M Buy
2,775,000
+2,047,500
+281% +$23.4M 1.59% 23
2025
Q2 		$6.93M Sell
727,500
-1,072,500
-60% -$11.8M 0.36% 50
2025
Q1 		$18.8M Buy
+1,800,000
New +$25.7M 1.34% 24
2024
Q3 		– Sell
-225,000
Closed -$7.94M – 75
2024
Q2 		$7.94M Buy
+225,000
New +$6.54M 0.59% 39

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vestal Point Capital's DYN Position: Q2 2026 in Review

Vestal Point Capital reduced its Dyne Therapeutics (DYN) stake by 16% in Q2 2026, selling an estimated $11.6M and leaving 3,375,000 shares worth $75M. The position accounts for 1.75% of the portfolio, ranked #20.

Vestal Point Capital first reported a position in DYN in Q2 2024 and has held it in 7 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Vestal Point Capital held 3,375,000 shares of Dyne Therapeutics worth $75M as of Q2 2026.
  • Vestal Point Capital sold 625,000 Dyne Therapeutics shares in Q2 2026, an estimated $11.6M.
  • Dyne Therapeutics made up 1.75% of Vestal Point Capital's portfolio in Q2 2026, its #20 holding.
  • Vestal Point Capital first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.